Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16757422 | 0.89 | KMT2A (0.73) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757155 | 0.89 | KMT2A (0.68) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757379 | 0.87 | KMT2A (0.67) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757144 | 0.85 | KMT2A (0.69) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16769442 | 0.85 | KMT2A (0.65) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757360 | 0.85 | KMT2A (0.91) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757078 | 0.84 | KMT2A (0.64) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757070 | 0.84 | KMT2A (0.64) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757211 | 0.84 | KMT2A (0.64) | KMT2AMEN1ALDH1A1KDM4ENPSR1 | |
| SCHEMBL16757075 | 0.84 | MEN1 (0.60) | KMT2AMEN1ALDH1A1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2017-01-05 | — | — | US | disclosed |
| EP-3074402-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-3074001-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015080988-A1 | BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015080949-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001988-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS AND CANCER | NCOR1, RRP15, NCOA1 | KMT2A 1974/4885MEN1 3157/4885ALDH1A1 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.